A recent study reports that loss of USP30 enhances mitophagy and reduces neurodegeneration by counteracting α‐synuclein's effects, and a USP30 inhibitor MTX115325 shows potential as a disease‐modifying therapy for PD.374. This evidence concerns the gene USP30 and Parkinson disease.